Les résultats et les conclusions des travaux menés par l’écosystème Experts Recherche Lymphome sont publiés dans des journaux médicaux de premier plan.
Lysa
2022_LYSA_Application of The Lugano Classification for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2- Technical)
DOI: 10.2967/jnumed.122.264124
En savoir plus
Lysa
2022_LYSA_Application of The Lugano Classification for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1- Clinical)
DOI: 10.2967/jnumed.122.264106
En savoir plus
Lysa
2022_LYSA_Influence of Sociodemographic Determinants on the Hodgkin Lymphoma Baseline Characteristics in Long Survivors Patients Enrolled in the Prospective Phase 3 Trial AHL2011
doi: 10.3390/cancers15010053
En savoir plus
Lysa
2022_LYSA_Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France
DOI: 10.1016/j.eclinm.2022.101674
En savoir plus
Lysa
2022_LYSA_Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP
DOI: 10.1038/s41375-022-01717-8
En savoir plus
Lysa
2022_LYSA_18F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients
DOI: 10.2967/jnumed.121.263501
En savoir plus
Lysa
2022_LYSA_A tumor volume and performance status model to predict outcome prior to treatment in diffuse large B-cell lymphoma
DOI: 10.1182/bloodadvances.2021006923
En savoir plus
Lysa
2022_LYSA_Finding a consensus on time-to-event endpoints definitions in marginal zone lymphoma: A Delphi method
DOI: 10.1002/hon.2988
En savoir plus
Lysa
2022_LYSA_Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma
DOI: 10.1002/ajh.26715
En savoir plus
Lysa
2022_LYSA_Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study
DOI: 10.1080/0284186X.2022.2130709
En savoir plus
Lysa
2022_LYSA_Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak
DOI: 10.1080/10428194.2022.2086249
En savoir plus
Lysa
2022_LYSA_Genomic profiling for clinical decision making in lymphoid neoplasms
DOI: 10.1182/blood.2022015854
En savoir plus
Lysa
2022_LYSA_Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population
DOI: 10.1016/j.ejca.2022.08.019
En savoir plus
Lysa
2022_LYSA_Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: A radio-genomic study
DOI: 10.1002/hon.3025
En savoir plus
Lysa
2022_LYSA_Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper
DOI: 10.1002/hon.3013
En savoir plus
Lysa
2022_LYSA_Prognostic value of FDG‐PET/CT response for patient selection before chimeric antigen receptor‐T‐cells therapy in non‐Hodgkin lymphoma
DOI: 10.1002/hon.2965
En savoir plus
Lysa
2022_LYSA_Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study
DOI: 10.1002/cam4.4742
En savoir plus
Lysa
2022_LYSA_Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV
DOI: 10.1182/bloodadvances.2022008355
En savoir plus
Lysa
2022_LYSA_The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
DOI: 10.1182/blood.2022015851
En savoir plus
Lysa
2022_LYSA_Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
DOI: 10.1182/bloodadvances.2022007371
En savoir plus
Lysa
2022_LYSA_Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma
DOI: 10.3324/haematol.2021.279561
En savoir plus
Lysa
2022_LYSA_The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
DOI: 10.1038/s41375-022-01620-2
En savoir plus
Lysa
2022_LYSA_End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma
DOI: 10.1111/bjh.18217
En savoir plus